DGAP-Adhoc: PAION AG: FDA CONSIDERS CURRENT HUMAN ABUSE LIABILITY PROGRAM WITH REMIMAZOLAM IN THE U.S. AS SUFFICIENT; NO SECOND INTRANASAL STUDY REQUIRED

2017. november 14., kedd, 10:15





DGAP-Ad-hoc: PAION AG / Key word(s): Research Update


PAION AG: FDA CONSIDERS CURRENT HUMAN ABUSE LIABILITY PROGRAM WITH REMIMAZOLAM IN THE U.S. AS SUFFICIENT; NO SECOND INTRANASAL STUDY REQUIRED


14-Nov-2017 / 10:15 CET/CEST


Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG.


The issuer is solely responsible for the content of this announcement.




FDA CONSIDERS CURRENT HUMAN ABUSE LIABILITY PROGRAM WITH REMIMAZOLAM IN THE U.S. AS SUFFICIENT; NO SECOND INTRANASAL STUDY REQUIRED



- The FDA has determined that the available studies are sufficient to provide necessary data regarding the abuse potential of remimazolam in humans



- No second intranasal study required



- PAION assumes clinical development program for remimazolam in procedural sedation in the U.S. as completed



Aachen (Germany), 14 November 2017 - The specialty pharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today announces that the FDA informed PAION last night that no additional study is required based on the submitted data. The FDA further informed PAION that it determines the abuse liability program conducted by PAION as sufficient to provide the necessary data regarding the abuse potential of remimazolam in humans. PAION therefore assumes the clinical development program for remimazolam in procedural sedation in the U.S. as completed and will now focus on finishing the respective reports.



The results of the abuse liability program will be part of the New Drug Application (NDA) for remimazolam in procedural sedation in the U.S., which partner Cosmo Pharmaceuticals currently expects to submit in the second half of 2018.



Based on the results of preclinical and Phase I studies and in consultation with the FDA, PAION had initiated additional Phase I studies to further assess the abuse potential of remimazolam. Two aspects were studied: if remimazolam could inappropriately be used as a knock-out cocktail in combination with alcohol and if it could be abused intranasally. Recruitment of a trial evaluating the oral administration of remimazolam with alcohol was completed in the third quarter of 2017. Recruitment of the first trial evaluating the intranasal administration of remimazolam was completed in the second quarter of 2017.


End of inside information



###



Contact

Ralf Penner

Vice President Relations/Public Relations

Martinstrasse 10-12

52062 Aachen - Germany

Phone +49 241 4453-152

E-mail r.penner@paion.com

www.paion.com



Disclaimer:

This release contains certain forward-looking statements concerning the future business of PAION AG. These forward-looking statements contained herein are based on the current expectations, estimates and projections of PAION AG"s management as of the date of this release. They are subject to a number of assumptions and involve known and unknown risks, uncertainties and other factors. Should actual conditions differ from the Company"s assumptions, actual results and actions may differ materially from any future results and developments expressed or implied by such forward-looking statements. Considering the risks, uncertainties and other factors involved, recipients should not rely unreasonably upon these forward-looking statements. PAION AG has no obligation to periodically update any such forward-looking statements to reflect future events or developments.











14-Nov-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

























Language: English
Company: PAION AG

Martinstr. 10-12

52062 Aachen

Germany
Phone: +49 (0)241-4453-0
Fax: +49 (0)241-4453-100
E-mail: info@paion.com
Internet: www.paion.com
ISIN: DE000A0B65S3
WKN: A0B65S
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange





 
End of Announcement DGAP News Service




628789  14-Nov-2017 CET/CEST







fncls.ssp?fn=show_t_gif&application_id=628789&application_name=news&site_id=geo_holding_tug
Tilos a hír bármilyen adatbázisba történő mentése vagy annak továbbítása harmadik fél számára;kereskedelmi viszonylatban vagy kereskedelmi céllal csak a Deutsche Gesellschaft für Ad-hoc-Publizität mbh írásos engedélyével történhet.